Skip to content
Is the FDA Too Cautious? episode artwork

Jul 21, 2023 53 min

Is the FDA Too Cautious?

from Open to Debate Hosted by Open to Debate

While the Food and Drug Administration (FDA) needs to approve safe and effective drugs as quickly as possible to patients who need them, it must also maintain the diligence and rigor necessary to prevent harm. Two health experts look at the pace of FDA approvals and argue about whether the agency is getting it right on keeping the public safe or stifling health innovations. Now we debate: Is the FDA Too Cautious? Arguing Yes: Colin Hill, CEO & Co-Founder, Aitia Arguing No: Peter Lurie, President and Executive Director of Center for Science in the Public Interest Emmy award-winning journalist John Donvan moderates

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Is the FDA Too Cautious?

0:00 53:15

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Open to Debate?

This episode is 53 minutes long.

When was this Open to Debate episode published?

This episode was published on July 21, 2023.

Can I download this Open to Debate episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.